الانتقال إلى المحتوى الرئيسي
xMedica

NCT07817251ClinicalTrials.gov

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…

المرحلة 3مطلوب 210 مشاركين40 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 210 participants (target), run at 40 sites.

How this score is built
  • Enrolment22/40

    210 participants (target)

  • Site count19/25

    40 sites

  • Country count0/15

    Single country

  • Planned duration4/10

    Planned over about 10 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 339 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

الحالات

  • Diabetes Mellitus, Type 2

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 210 مشاركين

الجهة الراعية والمتعاونون

  • Novo Nordisk A/S الجهة الراعية

الأذرع والتدخلات

  • CagriSema dose 1EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.

  • CagriSema dose 2EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.

  • CagriSema dose 3EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.

التدخلات

  • دواء CagriSema

    CagriSema will be administered s.c. once weekly.

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    الإطار الزمني From baseline (Week 0) to end of treatment (Week 16)

  2. مقياس النتيجة الثانوي

    Number of TEAEs

    Measured as count of events.

    الإطار الزمني From baseline (Week 0) to end of study (Week 22)

  3. مقياس النتيجة الثانوي

    Number of TEAEs

    Measured as count of events.

    الإطار الزمني From baseline (Week 0) to Week 8

  4. مقياس النتيجة الثانوي

    Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)

    Measured as count of episodes.

    الإطار الزمني From baseline (Week 0) to end of study (Week 22)

  5. مقياس النتيجة الثانوي

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    الإطار الزمني From baseline (Week 0) to end of study (Week 22)

  6. مقياس النتيجة الثانوي

    Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Measured as count of episodes.

    الإطار الزمني From baseline (Week 0) to Week 8

  7. مقياس النتيجة الثانوي

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    الإطار الزمني From baseline (Week 0) to Week 8

  8. مقياس النتيجة الثانوي

    Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)

    Measured as count of participants.

    الإطار الزمني From baseline (Week 0) to end of treatment (Week 16)

التواريخ

التواريخ
تاريخ البدء16 سبتمبر 2026 (فعلي)
الإتمام الأولي9 يونيو 2027 (تقديري)
الإتمام21 يوليو 2027 (تقديري)
أول نشر14 سبتمبر 2026 (فعلي)
آخر تحديث30 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

37 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Albuquerque Clinical Trials Inc.AlbuquerqueNew Mexicoقيد التجنيد
Amarillo Med Spec LLPAmarilloTexasقيد التجنيد
Texas Diabetes & EndocrinologyAustinTexasقيد التجنيد
Northern Pines Hlth Ctr, PCBuckleyMichiganقيد التجنيد
North Texas Endocrine CenterDallasTexasقيد التجنيد
Northeast Research InstituteFleming IslandFloridaقيد التجنيد
Diabetes and Thyroid Center of Fort WorthFort WorthTexasقيد التجنيد
Ark Clinical ResearchFountain ValleyCaliforniaقيد التجنيد
Gilbert Center For Family MedicineGilbertArizonaقيد التجنيد
Thrive Clinical Research GroupGlendoraCaliforniaقيد التجنيد
PharmQuest Life Sciences LLCGreensboroNorth Carolinaقيد التجنيد
AGA Clinical TrialHialeahFloridaقيد التجنيد
East West Med Res InstHonoluluHawaiiقيد التجنيد
JCCT- Juno NW HoustonHoustonTexasقيد التجنيد
Sante Clinical ResearchKerrvilleTexasقيد التجنيد
Scripps Whittier Diabetes InstLa JollaCaliforniaقيد التجنيد
Palm Research Center Inc-VegasLas VegasNevadaقيد التجنيد
DCOL Ctr for Clin ResLongviewTexasقيد التجنيد
Downtown LA Res Ctr. Inc.Los AngelesCaliforniaقيد التجنيد
Advanced Medical ResearchMaumeeOhioلم يبدأ التجنيد بعد
Adult Medicine of Lake County, IncMt. DoraFloridaقيد التجنيد
Clinical Research AssociatesNashvilleTennesseeقيد التجنيد
Tidewater Physicians Multispecialty GroupNewport NewsVirginiaقيد التجنيد
Alliance for Multispecialty ResearchNewtonKansasقيد التجنيد
North Hills Medical Research IncNorth Richland HillsTexasقيد التجنيد
Valley Clinical Trials, Inc.NorthridgeCaliforniaقيد التجنيد
Optimal Research SitesOrange CityFloridaقيد التجنيد
Dream Team Clinical ResearchPomonaCaliforniaقيد التجنيد
Clinical Trials Research_SacramentoSacramentoCaliforniaقيد التجنيد
J.Lewis Research IncSalt Lake CityUtahقيد التجنيد
NE Clin Res of San AntonioSan AntonioTexasلم يبدأ التجنيد بعد
Linda Vista Health Care CtrSan DiegoCaliforniaقيد التجنيد
Diabetes & Endo Treatment SpecSandy CityUtahلم يبدأ التجنيد بعد
Endeavor HealthSkokieIllinoisقيد التجنيد
Chrysalis Clinical ResearchSt. GeorgeUtahقيد التجنيد
Cotton O'Neil Diabetes & EndocrinologyTopekaKansasقيد التجنيد
Chase Medical Research LLCWaterburyConnecticutقيد التجنيد
Iowa Diabetes & Endo Res CtrWest Des MoinesIowaقيد التجنيد
Metabolic Research Institute IncWest Palm BeachFloridaقيد التجنيد
Accellacare WilmingtonWilmingtonNorth Carolinaقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 30 سبتمبر 2026

    تغيّرت الحالة

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 30 سبتمبر 2026

    فُتح التجنيد

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING